Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Jacot

Showing results (61-70 of 212) with videos related to

Pageof 22
Sort By:
Bulletin Du Cancer|July 8, 2026
Determinants of return to work in long-term metastatic breast cancer survivors: Results of a multicenter French cohortMarylou Fouquet, Bertrand Porro, Julien Robert, et al.
Clinical Chemistry and Laboratory Medicine|June 22, 2013
Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantificationAnna Durigova, Pierre-Jean Lamy, Simon Thezenas, et al.
Breast Cancer Research : BCR|February 4, 2011
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancersPierre-Jean Lamy, Frédéric Fina, Caroline Bascoul-Mollevi, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2021
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapyFanny Leenhardt, Marie Alexandre, Severine Guiu, et al.
Cancers|October 14, 2022
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast CancerAngélique Bobrie, Océane Massol, Jeanne Ramos, et al.
Breast Cancer Research : BCR|December 24, 2011
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profilesWilliam Jacot, Evelyne Lopez-Crapez, Simon Thezenas, et al.
BMC Cancer|March 6, 2014
Age and stage at diagnosis: a hospital series of 11 women with intellectual disability and breast carcinomaDaniel Satgé, Eric-André Sauleau, William Jacot, et al.
Cancer Letters|April 4, 2024
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast CancerEsin Orhan, Carolina Velazquez, Imene Tabet, et al.
Cancers|December 10, 2021
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersWilliam Jacot, Aurélie Maran-Gonzalez, Océane Massol, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancerMohammad Chakra, Jean Louis Pujol, Pierre-Jean Lamy, et al.
Pageof 22

Showing results (61-70 of 212) with videos related to

Sort By:
Pageof 22
Bulletin Du Cancer|July 8, 2026
Determinants of return to work in long-term metastatic breast cancer survivors: Results of a multicenter French cohortMarylou Fouquet, Bertrand Porro, Julien Robert, et al.
Clinical Chemistry and Laboratory Medicine|June 22, 2013
Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantificationAnna Durigova, Pierre-Jean Lamy, Simon Thezenas, et al.
Breast Cancer Research : BCR|February 4, 2011
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancersPierre-Jean Lamy, Frédéric Fina, Caroline Bascoul-Mollevi, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2021
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapyFanny Leenhardt, Marie Alexandre, Severine Guiu, et al.
Cancers|October 14, 2022
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast CancerAngélique Bobrie, Océane Massol, Jeanne Ramos, et al.
Breast Cancer Research : BCR|December 24, 2011
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profilesWilliam Jacot, Evelyne Lopez-Crapez, Simon Thezenas, et al.
BMC Cancer|March 6, 2014
Age and stage at diagnosis: a hospital series of 11 women with intellectual disability and breast carcinomaDaniel Satgé, Eric-André Sauleau, William Jacot, et al.
Cancer Letters|April 4, 2024
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast CancerEsin Orhan, Carolina Velazquez, Imene Tabet, et al.
Cancers|December 10, 2021
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersWilliam Jacot, Aurélie Maran-Gonzalez, Océane Massol, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancerMohammad Chakra, Jean Louis Pujol, Pierre-Jean Lamy, et al.
Pageof 22